CONFIRMATION-HF will further this research by investigating Finerenone combined with SGLT2 inhibitors in a broader HF population, regardless of the LVEF, with the goal of reducing heart failure events and cardiovascular mortality [40]. The gene discussed is SLC5A2; the disease is heart failure.